SynerFuse has filed a notice of an exempt offering of securities to raise $25 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, SynerFuse is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Justin Zenanko played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About SynerFuse
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. SynerFuse is long-term pain management without the use of addictive opioids. SynerFuse combines two FDA-approved technologies and synergistically fuses both in order to attack the problem of long-term, post-surgery, lower back pain, with a preemptive, drug-free pain management system.
To learn more about SynerFuse, visit http://www.synerfuse.com/
Contact:
Justin Zenanko, Chief Executive Officer
612-217-2914
https://www.linkedin.com/in/justin-zenanko-83641864/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.